CTI BioPharma (United Kingdom)

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text

Cell Therapy, Immunology, Immune Regulation +17

Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product

Helene M. Finney, Alastair D. G. Lawson, Christopher Bebbington et al. · The Journal of Immunology · 1998 · 532 citations · Full text

Effects of an Engineered Human Anti–TNF-α Antibody (CDP571) on Insulin Sensitivity and Glycemic Control in Patients With NIDDM

Francis Ofei, Steve Hurel, José Newkirk et al. · Diabetes · 1996 · 510 citations

Membrane‐Type Matrix Metalloproteinases 1 and 2 Exhibit Broad‐Spectrum Proteolytic Capacities Comparable to Many Matrix Metalloproteinases

Marie‐Pia d’Ortho, Horst Will, Susan J. Atkinson et al. · European Journal of Biochemistry · 1997 · 437 citations

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Patrick Hayden, Claire Roddie, Peter Bader et al. · Annals of Oncology · 2021 · 389 citations · Full text